Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events

PURPOSE: Due to shared hepatic metabolism, concomitant medication with a proton pump inhibitor (PPI) and clopidogrel might reduce the effectiveness of clopidogrel in the prevention of cardiovascular events after percutaneous coronary intervention (PCI). We aimed to examine the risk of major cardiova...

Descripción completa

Detalles Bibliográficos
Autores principales: Maret-Ouda, John, Santoni, Giola, Xie, Shaohua, Rosengren, Annika, Lagergren, Jesper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652231/
https://www.ncbi.nlm.nih.gov/pubmed/34241731
http://dx.doi.org/10.1007/s10557-021-07219-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652231/
https://www.ncbi.nlm.nih.gov/pubmed/34241731
http://dx.doi.org/10.1007/s10557-021-07219-6

Ejemplares similares